Dostarlimab “A Miracle Drug Against Cancer”: Current Knowledge and On-going Clinical Trials
Keywords:Dostarlimab, Locally advanced rectal cancer, Mismatch repair deficient (dMMR) recurrent or advanced solid tumors, GARNET trial, Monoclonal antibodies, Cancer immunotherapy, Clinical trials
Cancer stands as one of the leading causes of death globally. Its socio-economic burden is increasing day by day. There is no defined treatment strategy for cancer. In most of the cases a combinatorial therapy approach is utilised which includes surgery, chemotherapy, immune therapy, radiation therapy etc. Immune checkpoints are a revolutionary discovery in cancer immunotherapy. Dostarlimab is an anti-programmed cell death protein-1 (PD-1) immunoglobulin G4 (IgG4) humanised monoclonal antibody (mAb), produced by recombinant DNA technology in mammalian Chinese hamster ovary (CHO) cells. PD-1 is an immune checkpoint receptor expressed by T-cells which has shown to suppress cancer-specific immune responses. In this article we provide the recent known information regarding dostarlimab along with currently undergoing 44 clinical trials globally with its title, conditions, interventions, and outcome measures.
How to Cite
Copyright (c) 2022 Mohammed Asadullah Jahangir, Nitesh Kumar and Mohammed Shadab Shahab
This work is licensed under a Creative Commons Attribution 4.0 International License.